Novo Nordisk Pushes on Two Fronts: Pill Adoption Surges as Implant Partnership Takes Shape
Veröffentlicht: 07.07.2026 um 18:54 Uhr, Redaktion boerse-global.de
The Danish pharma giant is accelerating its assault on the obesity market from two distinct angles, pairing a blockbuster oral rollout with a long-term bet on implantable drug delivery. The strategy is already winning over analysts, even as technical indicators flash a note of caution.
Novo Nordisk’s oral Wegovy tablet has gained rapid traction in the US since its launch, capturing roughly 65% of all new prescriptions in the first quarter. That momentum helped the drug generate around $353.6 million in that period alone, comfortably beating consensus estimates. The momentum is now being exported: Wegovy’s pill form became available in the UK on a private-payer basis this week, with a starter pack priced at £69 and a monthly top dose running about £189. The National Health Service has yet to decide on reimbursement, but the company is banking on strong private demand.
Clinical data support the push: patients using the tablet shed up to 17% of their body weight over roughly a year. Meanwhile, UK regulators have approved semaglutide – Wegovy’s active ingredient – for an additional indication, advanced liver fibrosis, opening a fresh therapeutic front.
On the pipeline side, Novo Nordisk is looking beyond daily pills. The company inked a non-exclusive agreement with Vivani Medical to evaluate NPM-139, a miniature semaglutide implant designed to deliver sustained drug release over an extended period. The partners plan to begin a Phase 1 study by mid-2026, using the existing Wegovy injection as a comparator. Financial terms of the collaboration were not disclosed.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analysts are taking notice. Danske Bank raised its price target on Novo Nordisk to 365 Danish kroner and reiterated a buy rating, citing strong US prescription data and the UK launch. The bank also lifted its revenue forecasts for the oral formulation.
Not all news was rosy. In Sweden, the TLV reimbursement authority rejected a subsidy application for an obesity drug in children, citing a pending appeal on an earlier request. Novo Nordisk Sweden expressed disappointment, though the decision is unlikely to move the needle in a market dominated by US and UK dynamics.
A bigger challenge looms in America. Starting January 2027, Novo Nordisk plans to cut Wegovy’s US list price by roughly 50% and Ozempic’s by about 35%. While the discounts will squeeze revenue per unit, they are aimed at widening access and boosting prescription volumes.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The stock has already priced in plenty of optimism. Shares closed Tuesday at €43.56, up 0.75% on the day, extending a monthly rally of more than 22%. The recovery from its March 52-week low of €30.25 now stands at some 44%. Yet the 14-day relative strength index has climbed to 70.2, touching overbought territory. The share price sits more than 11% above its 50-day moving average of €39.05, leaving little room for error heading into the second-quarter earnings report due on August 5. That print will be the market’s next test of whether the pill’s dizzying rise has legs.
Ad
Novo Nordisk Stock: New Analysis - 7 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
